Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma

Conclusions The efficacy of current second-line therapy in PD NEC is poor. No second-line regimen showed statistically significant superiority. Cisplatin was associated with longer OS regardless of second-line regimen or age. However, unmeasured confounders such as performance status or comorbidities may explain this effect.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research